Zhang Zhuo, Li Mao, Rayburn Elizabeth R, Hill Donald L, Zhang Ruiwen, Wang Hui
Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama, Birmingham, Alabama 35294-0019, USA.
Am J Pharmacogenomics. 2005;5(6):397-407. doi: 10.2165/00129785-200505060-00006.
This is the final part of a four-part serial review on oncogenes and their potential use as targets for cancer therapy. Previous sections discussed various categories of oncogenes (growth factors, tyrosine kinases, intermediate signaling molecules, and transcription factors) and the advances made in various strategies being used to alter their actions. This part describes four oncogenes, MDM2, BCL2, XIAP, and Survivin, that are involved in regulation of the cell cycle and apoptosis.
这是关于癌基因及其作为癌症治疗靶点潜在用途的四部分系列综述的最后一部分。前几部分讨论了各类癌基因(生长因子、酪氨酸激酶、中间信号分子和转录因子)以及在改变其作用的各种策略方面取得的进展。本部分描述了参与细胞周期调控和细胞凋亡的四个癌基因,即MDM2、BCL2、XIAP和Survivin。